Dare Bioscience

Dare Bioscience Current Assets

The Current Assets of Dare Bioscience (DARE) as of Nov 2, 2026 is 26.49 M USD. In the previous year, Current Assets was 18.22 M USD — a change of 45.41% (higher).

Current Assets

26.49 MUSD

YoY

45.41%

Last updated:

Current Assets of Dare Bioscience is 2025 26.49 M USD. Current Assets of Dare Bioscience was 2024 18.22 M USD. It decreases by 45.41% higher compared to the previous year.

The Dare Bioscience Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
-395.48 M USD
Jan 1, 2019
-1.10 B USD
Jan 1, 2020
-1.85 B USD
Jan 1, 2021
-2.42 B USD
Jan 1, 2022
41.34 M USD
Jan 1, 2023
16.59 M USD
Jan 1, 2024
18.22 M USD
Jan 1, 2025
26.49 M USD
The Dare Bioscience Current Assets history
YEARCurrent AssetsYoY
26.49 MUSD+45.41%
18.22 MUSD+9.78%
16.59 MUSD-59.85%
41.34 MUSD-101.71%
-2.42 BUSD+31.10%
-1.85 BUSD+67.56%
-1.10 BUSD+178.55%
-395.48 MUSD-4,821.37%
8.38 MUSD-76.03%
34.95 MUSD-54.79%
77.30 MUSD+46.30%
52.83 MUSD+719.39%
6.45 MUSD-62.22%
17.07 MUSD+8.88%
15.68 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

Current Assets of Dare Bioscience is 26.49 M USD in 2025.

Current Assets of Dare Bioscience changed from 18.22 M USD to 26.49 M USD, representing a 45.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Dare Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Dare Bioscience

All Key Metrics — Dare Bioscience